Ultimovacs ASA at Redeye Investor AW Transcript
Now, it's time for Ultimovacs along with CEO Carlos de Sousa. Welcome.
Okay. Thank you. Good evening, everybody. My name is Carlos de Sousa. Thank you for being here and listen to Ultimovacs.
Ultimovacs is a biotech company located in Oslo. And because we are publicly listed, I need to show you this slide. I'm sorry first that I cannot do it in Swedish, but after the -- all presentations, if there are any questions, I will be here to answer.
Let me tell you what we do as a company. We work with a new generation of cancer vaccines. Cancer vaccines are becoming now more visible and rising in importance, particularly because some of the versions of old cancer vaccines were used to produce the COVID vaccines. Also a very recent deal where Merck acquired the cancer vaccine part of Moderna. That's one of the COVID. So really raised the interest more and more for cancer vaccines.
We have several benefits as a cancer vaccine. One is we are what is called off-the-shelf
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
